Why the study?
Does inhibition of MEF2A improve diabetic cardiac fibrosis in STZ-induced diabetic mice?
Does inhibition of MEF2A improve diabetic cardiac fibrosis in STZ-induced diabetic mice?
Inhibition of endothelial cell-derived MEF2A may prevent diabetes mellitus-induced cardiac fibrosis by partially inhibiting EndMT through interaction with p38MAPK and Smad2.
MEF2A inhibition may attenuate post-MI remodeling; leaves open human translation and prospective trials.
// Xue-ying Chen 1, * , Rui-juan Lv 2, * , Wei Zhang 1 , Yu-gang Yan 4 , Peng Li 3 , Wen-qian Dong 1 , Xue Liu 1 , Er-shun Liang 1 , Hong-liang Tian 1 , Qing-hua Lu 5 , Ming-xiang Zhang 1 1 The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital of Shandong University, Jinan, Shandong, China 2 Department of Emergency, Qilu Hospital of Shandong University, Jinan, Shandong, China 3 College of Pharmacy, Xinxiang Medical University, Xinxiang, China 4 Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Jinan, Shandong, China 5 Department of Cardiology, The Second Hospital of Shandong University, Jinan, Shandong, China * These authors have contributed equally to this work Correspondence to: Ming-Xiang Zhang, e-mail: zhangmingxiang@sdu.edu.cn Qing-hua Lu, e-mail: lqhzhy@163.com Keywords: myocyte-specific enhancer factor 2A, fibrosis, diabetes mellitus, endothelial mesenchymal transition Received: September 29, 2015 Accepted: March 31, 2016 Published: April 20, 2016 ABSTRACT Cardiac fibrosis is an important pathological process of diabetic cardiomyopathy, the underlying mechanism remains elusive. This study sought to identify whether inhibition of Myocyte enhancer factor 2A (MEF2A) alleviates cardiac fibrosis by partially regulating Endothelial-to-mesenchymal transition (EndMT). We induced type 1 diabetes mellitus using the toxin streptozotocin (STZ) in mice and injected with lentivirus-mediated short-hairpin RNA (shRNA) in myocardium to inhibit MEF2A expression. Protein expression, histological and functional parameters were examined twenty-one weeks post-STZ injection. We found that Diabetes mellitus increased cardiac MEF2A expression, aggravated cardiac dysfunction and myocardial fibrosis through the accumulation of fibroblasts via EndMT. All of these features were abolished by MEF2A inhibition. MEF2A gene silencing by shRNA in cultured human umbilical vein endothelial cells (HUVECs) ameliorated high glucose–induced phenotypic transition and acquisition of mesenchymal markers through interaction with p38MAPK and Smad2. We conclude that inhibition of endothelial cell-derived MEF2A might be beneficial in the prevention of diabetes mellitus-induced cardiac fibrosis by partially inhibiting EndMT through interaction with p38MAPK and Smad2.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: